Page 3 of 6
Which patients were included in this study?
Studies have a list of requirements for patients who can enrol (inclusion criteria) and
those who can’t (exclusion criteria). For this study, the main inclusion and exclusion
criteria are listed below.
Men and women with chronic hepatitis B were included in the study if they:
• Were between 20 and 69 years old.
• Were taking ETV for at least two years before starting the study
treatment and:
Their blood tested positive for the presence of HBeAg and HBsAg
o
proteins at the start of the study.
Their blood tested negative for the presence of HBV DNA at the start
o
of the study.
Men and women were excluded from the study if they had:
• Cancer or signs of disease in the liver.
• Infection with HIV or hepatitis C virus.
• Received hepatitis B vaccine or were treated with interferon (protein)
within six months before starting the study.
• Received treatment with other anti-viral medicines, including TDF,
adefovir, or tenofovir alafenamide fumarate, within two years before
starting the study treatment.
• An organ or bone marrow transplant or planned to have one.
• Any other disease(s) or treatment(s) that the study doctor thought
would affect the results of the study.
Overall, 75 patients received at least one dose of TDF. The study included 55 (73%)
men and 20 (27%) women. The average age was 48 years. The youngest patient was
33 years old and the oldest patient was 69 years old.